SCHEMBL84270

SCHEMBL84270

CC(O)c1cccc(C#N)c1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
CYP1A2 P05177 3/20 0.35
CYP3A4 P08684 3/20 0.35
MAPK1 P28482 2/20 0.35
ADRB2 P07550 2/20 0.35
ADRB1 P08588 2/20 0.35
ADRB3 P13945 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MAP2K1 Q02750 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
LMNA P02545 2/20 0.33
HTR2B P41595 2/20 0.33
FAAH O00519 1/20 0.33
GABRA1 P14867 1/20 0.33
HPGD P15428 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
PTGS1 P23219 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19768970 0.89 GABRA1 (0.40) TSHRL3MBTL1CYP1A2CYP3A4ALDH1A1
SCHEMBL536175 0.80 TSHR (0.46) TSHRL3MBTL1MAPK1ALDH1A1CA1
SCHEMBL343227 0.80 TSHR (0.46) TSHRL3MBTL1MAPK1ALDH1A1CA1
SCHEMBL20621249 0.79 TSHR (0.43) TSHRL3MBTL1CYP1A2CYP3A4MAPK1
SCHEMBL26596713 0.79 ALDH1A1 (0.35) TSHRL3MBTL1CYP1A2CYP3A4MAPK1
SCHEMBL21883592 0.77 CYP1A2 (0.34) TSHRL3MBTL1CYP1A2CYP3A4ALDH1A1
SCHEMBL19779659 0.76 TSHR (0.39) TSHRL3MBTL1CYP1A2CYP3A4ALDH1A1
SCHEMBL14081995 0.76 GABRA1 (0.52) TSHRCYP1A2CYP3A4CA1CA2
SCHEMBL27591378 0.75 ALDH1A1 (0.38) TSHRL3MBTL1ALDH1A1LMNASMN1; SMN2
SCHEMBL2423501 0.75 TSHR (0.46) TSHRCYP1A2CYP3A4ALDH1A1MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122892-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-05-17 US disclosed
US-8129403-B2 e.g. 2-[9-(5-Cyclopropyl-1H-pyrazol-3-yl)-6-methyl-9H-purin-2-ylamino]-2-(4-fluorophenyl)ethanol; tropomyosin-related kinases (Trk's) inhibitor; anticarcinoganic agent; solid tumors and leukemia ASTRAZENECA AB (SE) 2012-03-06 US disclosed
US-20090227648-A1 PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER ASTRAZENECA AB 2009-09-10 US disclosed
US-20080176872-A1 Chemical Compounds ASTRAZENECA AB (SE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176872-A1 Chemical Compounds TP53, XPOT, KRAS TSHR 4679/4885L3MBTL1 4616/4885CYP1A2 69/4885
US-20120122892-A1 CHEMICAL COMPOUNDS TP53, XPOT, KRAS TSHR 4676/4885L3MBTL1 4633/4885CYP1A2 59/4885
US-20090227648-A1 PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER TP53, PDK2, PDK1 TSHR 3060/4885L3MBTL1 4459/4885CYP1A2 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.